Observational studyNutrients2025
Can Faecal Eosinophil Cationic Protein and β-Defensin-2 Levels Be Useful in the Diagnosis and Follow-Up of Infants with Milk-Protein-Induced Allergic Proctocolitis?
Observational study in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct Inflammation-Associated Microbiome Signatures in Pediatric Non-IgE-Mediated Food Allergy.International journal of molecular sciences · 2026Article
- Special Issue: Diet and Lifestyle Factors Associated with Allergic Diseases in Early Life.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe aim of our study was to investigate whether faecal concentrations of eosinophil cationic protein (fECP) and human β-defensins (HBD2s) are significantly elevated in children with cow's milk-protein-induced allergic colitis (MPIAP) and whether a monthly milk-free diet reduces these markers. MATERIALS AND
methodsThis was a single-centre, prospective, observational cohort study involving 70 infants with MPIAP, aged 1-3 months, and 30 healthy controls of the same age. The concentrations of fECP and HBD2 were measured using the ELISA method (IDK
resultsThe concentrations of fECP and HBD2 proved useful in evaluating MPIAP treatment with a milk-free diet, where the resolution of allergy symptoms and a significant (
conclusionsfECP and HBD2 can be used to monitor the resolution of colitis in infants with MPIAP treated with a milk diet, indicating a slower resolution of allergic inflammation than the resolution of allergic symptoms. Therefore, neither of the parameters are useful for the diagnosis of MPIAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.